Here, we evaluate the cost-effectiveness of the once-daily GLP-1RA liraglutide added to basal insulin, compared with once-daily lixisenatide added to basal insulin, for Swedish patients with T2D, using a validated cost-effectiveness model. Here, INS is linked to type 2 diabetes mellitus.